DOP2012000150A - Triazolopiridinas - Google Patents

Triazolopiridinas

Info

Publication number
DOP2012000150A
DOP2012000150A DO2012000150A DO2012000150A DOP2012000150A DO P2012000150 A DOP2012000150 A DO P2012000150A DO 2012000150 A DO2012000150 A DO 2012000150A DO 2012000150 A DO2012000150 A DO 2012000150A DO P2012000150 A DOP2012000150 A DO P2012000150A
Authority
DO
Dominican Republic
Prior art keywords
compounds
preparing
triazolopiridins
prophylaxis
disease
Prior art date
Application number
DO2012000150A
Other languages
English (en)
Inventor
Hans Briem
Dirk Kosemund
Gerhard Siemeister
Marcus Koppitz
Hartmut Schirok
Ulf Bomer
Volker Schulze
Benjamin Bader
Philip Lienau
Antje Margret Wengner
Simon Holton
Stefan Prechtl
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of DOP2012000150A publication Critical patent/DOP2012000150A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Abstract

Compuestos de triazolopiridina de la fórmula general donde R, R2, R3, R4 y R5 tienen los valores que se definen en la descripción y en las reivindicaciones. Métodos para preparar dichos compuestos. Composiciones y combinaciones farmacéuticas que comprenden dichos compuestos. Uso de dichos compuestos para preparar una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad. Compuestos intermediarios útiles para preparar dichos compuestos.
DO2012000150A 2009-11-30 2012-05-30 Triazolopiridinas DOP2012000150A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09075535A EP2343297A1 (en) 2009-11-30 2009-11-30 Triazolopyridines

Publications (1)

Publication Number Publication Date
DOP2012000150A true DOP2012000150A (es) 2012-09-30

Family

ID=42028156

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000150A DOP2012000150A (es) 2009-11-30 2012-05-30 Triazolopiridinas

Country Status (36)

Country Link
US (1) US9676766B2 (es)
EP (2) EP2343297A1 (es)
JP (1) JP5805653B2 (es)
KR (1) KR20120115290A (es)
CN (1) CN102762557B (es)
AR (1) AR079166A1 (es)
AU (1) AU2010324155B2 (es)
BR (1) BR112012012906A2 (es)
CA (1) CA2781915A1 (es)
CL (1) CL2012001391A1 (es)
CR (1) CR20120295A (es)
CU (1) CU24100B1 (es)
CY (1) CY1115866T1 (es)
DK (1) DK2507235T3 (es)
DO (1) DOP2012000150A (es)
EA (1) EA022353B1 (es)
EC (1) ECSP12011935A (es)
ES (1) ES2525069T3 (es)
GT (1) GT201200165A (es)
HK (1) HK1178153A1 (es)
HN (1) HN2012001162A (es)
HR (1) HRP20141093T1 (es)
IL (1) IL219750A (es)
MA (1) MA33768B1 (es)
MX (1) MX2012006252A (es)
MY (1) MY160325A (es)
NZ (1) NZ600229A (es)
PE (1) PE20121509A1 (es)
PL (1) PL2507235T3 (es)
PT (1) PT2507235E (es)
RS (1) RS53670B1 (es)
SI (1) SI2507235T1 (es)
TN (1) TN2012000265A1 (es)
UA (1) UA108486C2 (es)
WO (1) WO2011063908A1 (es)
ZA (1) ZA201203806B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
CA2821829A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103429591A (zh) 2010-12-17 2013-12-04 拜耳知识产权有限责任公司 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪
ES2530802T3 (es) 2010-12-17 2015-03-06 Bayer Ip Gmbh Imidazopirazinas 6-tiosustituidas para uso como inhibidores de MPS-1 y TKK en el tratamiento de trastornos hiperproliferativos
US9284317B2 (en) 2010-12-17 2016-03-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
JP2013545779A (ja) 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
CN103370322B (zh) 2010-12-17 2016-02-10 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪
ES2571741T3 (es) 2011-03-31 2016-05-26 Bayer Ip Gmbh Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa
ES2545135T3 (es) 2011-04-06 2015-09-08 Bayer Pharma Aktiengesellschaft Imidazopiridinas sustituidas y compuestos intermedios de las mismas
US20140120087A1 (en) * 2011-04-21 2014-05-01 Bayer Intellectual Property Gmbh Triazolopyridines
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
BR112015000308A2 (pt) * 2012-07-10 2017-06-27 Bayer Pharma AG método para preparo de triazolopiridinas substituídas
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
US9682995B2 (en) 2013-01-30 2017-06-20 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
EP3004092B1 (en) * 2013-06-07 2017-03-22 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
AU2014280356A1 (en) * 2013-06-11 2015-12-24 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
CA2914742A1 (en) 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Handovers with co-operating cells configured to provide coordinated multi-point transmission/reception
EP2980088A1 (en) 2014-07-28 2016-02-03 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
USRE48974E1 (en) 2014-04-07 2022-03-15 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-E]indolizines
EP2977375A1 (en) 2014-07-25 2016-01-27 Bayer Pharma Aktiengesellschaft Amino-substituted isoxazoles
EP2977377A1 (en) 2014-07-25 2016-01-27 Bayer Pharma Aktiengesellschaft Amino-substituted isoxazoles
EP2977376A1 (en) 2014-07-25 2016-01-27 Bayer Pharma Aktiengesellschaft Amino-substituted isoxazoles
PL3283642T3 (pl) 2015-04-17 2024-04-22 Crossfire Oncology Holding B.V. Biomarkery prognostyczne dla chemioterapii inhibitorem TTK
KR101686411B1 (ko) * 2015-12-28 2016-12-14 한국원자력의학원 피리딘계 유도체를 포함하는 암 예방 또는 치료용 조성물
CN107641118B (zh) * 2016-07-22 2020-11-06 爱科诺生物医药股份有限公司 具有细胞坏死抑制活性的化合物及其组合物和应用
JP7023217B2 (ja) 2017-12-01 2022-02-21 ダイキン工業株式会社 アルカリ接触する表面を有する構成要素
WO2020097400A1 (en) * 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
JP2023525047A (ja) 2020-05-06 2023-06-14 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害薬としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
WO2022178340A2 (en) * 2021-02-22 2022-08-25 Orgenesis Inc. Pharmaceutical compositions comprising ranpirnase
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
WO2005030121A2 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds, compositions and methods
BRPI0516819A (pt) 2004-10-07 2008-09-23 Warner Lambert Co derivados de triazolopiridina e agentes antibacterianos
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
EA200870592A1 (ru) 2006-05-31 2009-08-28 Галапагос Н.В. Триазолопиразиновые соединения, пригодные для лечения дегенеративных и воспалительных заболеваний
EP2057158B8 (en) 2006-08-30 2015-09-30 Cellzome Limited Triazole derivatives as kinase inhibitors
MX2010000716A (es) * 2007-07-18 2010-03-26 Novartis Ag Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa.
KR20100057650A (ko) * 2007-08-23 2010-05-31 아스트라제네카 아베 증식성 질환의 치료를 위한 ｔｔｋ／ｍｐｓ１의 억제제로서 ２-아닐리노푸린-８-온
WO2009027283A1 (en) * 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2008328882A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as PI3K inhibitors
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
EA201101188A1 (ru) * 2009-02-13 2012-04-30 Фовеа Фармасьютикалз [1,2,4]триазоло[1,5-а]пиридины в качестве ингибиторов киназы
CA2760077A1 (en) 2009-04-29 2010-11-04 Marcus Koppitz Substituted imidazoquinoxalines
US9340528B2 (en) 2009-09-04 2016-05-17 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
MX2012008259A (es) 2010-01-15 2012-08-17 Janssen Pharmaceuticals Inc Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa.
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators

Also Published As

Publication number Publication date
UA108486C2 (en) 2015-05-12
BR112012012906A2 (pt) 2017-03-01
US9676766B2 (en) 2017-06-13
IL219750A0 (en) 2012-07-31
CA2781915A1 (en) 2011-06-03
CN102762557B (zh) 2015-10-07
DK2507235T3 (en) 2014-12-15
KR20120115290A (ko) 2012-10-17
CN102762557A (zh) 2012-10-31
EP2507235A1 (en) 2012-10-10
EP2507235B1 (en) 2014-10-22
ES2525069T3 (es) 2014-12-17
SI2507235T1 (sl) 2015-01-30
TN2012000265A1 (en) 2013-12-12
IL219750A (en) 2014-02-27
AR079166A1 (es) 2011-12-28
EA022353B1 (ru) 2015-12-30
GT201200165A (es) 2014-01-03
ECSP12011935A (es) 2012-07-31
PL2507235T3 (pl) 2015-03-31
US20120328610A1 (en) 2012-12-27
WO2011063908A1 (en) 2011-06-03
CL2012001391A1 (es) 2012-10-26
AU2010324155B2 (en) 2015-10-01
EP2343297A1 (en) 2011-07-13
HN2012001162A (es) 2015-08-10
PT2507235E (pt) 2014-12-11
MX2012006252A (es) 2012-09-07
RS53670B1 (en) 2015-04-30
HK1178153A1 (zh) 2013-09-06
EA201200794A1 (ru) 2013-03-29
CY1115866T1 (el) 2017-01-25
MA33768B1 (fr) 2012-11-01
NZ600229A (en) 2014-06-27
JP2013512264A (ja) 2013-04-11
CU20120084A7 (es) 2012-10-15
CR20120295A (es) 2012-07-30
CU24100B1 (es) 2015-07-30
PE20121509A1 (es) 2012-11-18
ZA201203806B (en) 2013-07-31
AU2010324155A1 (en) 2012-06-07
HRP20141093T1 (hr) 2015-01-16
MY160325A (en) 2017-02-28
JP5805653B2 (ja) 2015-11-04

Similar Documents

Publication Publication Date Title
DOP2012000150A (es) Triazolopiridinas
DOP2014000133A (es) Triazolopiridinas sustituidas
DOP2013000244A (es) Triazolopiridinas
ECSP12012338A (es) Triazolopiridinas sustituidas
CO2017001035A2 (es) “2-(morfolin-4-il)-1,7-naftiridinas sustituidas, composiciones y combinaciones farmacéuticas que las comprenden, y compuestos intermediarios
DOP2011000218A (es) Derivados de sulfonamida
CR20110609A (es) Composicion antimicrobiana y metodos relacionados de uso
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
ECSP088963A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmacéuticas que las comprenden
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
CR20160016A (es) Pirazolpiridinas sustituidas
UY31922A (es) Compuestos
SV2010003773A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
CL2011003355A1 (es) Compuestos derivados de alcoxi-carbonil-amino-alquinil-adenosina ; composición farmacéutica que los comprende; uso del compuesto en la preparación de un medicamento útil para tratar enfermedades autoinmunes, inflamatorias, alérgicas, infecciosas entre otras.
BR112012031289A2 (pt) novos derivados 1,4-diazepanos, inibidores de pde-5
CU20130141A7 (es) Triazolopiridinas